Robert Langer Joins in Daré Bioscience, Inc. Scientific Advisory Board
March 29, 2019 at 08:00 am EDT
Share
Daré Bioscience, Inc. announced that Dr. Robert Langer, co-inventor of Daré‘s novel, segmented intravaginal ring drug delivery technology and one of the 10 Institute Professors at the Massachusetts Institute of Technology (MIT) joined the company’s Scientific Advisory Board. In his work at MIT, Dr. Langer’s research focuses on the integration of medicine, materials science and chemical engineering. His pioneering work in biotechnology began when he joined Dr. Judah Folkman’s cancer researcher lab at the Children's Hospital Boston.
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.